Destiny Pharma : Result of 2024 Annual General Meeting
June 13, 2024 at 08:47 am
Share
DESTINY PHARMA PLC
Results of the Annual General Meeting held on 12 June 2024
Resolution
Votes for
% of votes
Votes
% of votes
Votes
cast
against
cast
withheld
1
To receive and accept the
21,039,507
99.54
97,425
0.46
581,342
strategic report, directors'
report, auditor's report and
financial statements
2
To re-elect Dr William Love
21,382,475
98.45
335,799
1.55
-
as a director
3
To elect Sir Nigel Rudd as a
21,420,398
98.63
297,876
1.37
-
director
4
To elect Christopher Tovey as
21,419,761
98.63
298,513
1.37
-
a director
5
To re-appoint Crowe U.K. LLP
21,419,927
98.63
298,347
1.37
-
as Auditor to the Company
6
To authorise the Audit
21,417,969
98.64
295,860
1.36
4,445
Committee to determine the
remuneration of the Auditor
7
To authorise the directors to
21,393,550
98.60
304,724
1.40
20,000
allot ordinary shares
8
Subject to Resolution 7, to
21,389,105
98.60
304,724
1.40
24,445
disapply statutory pre-
emption rights in relation to
the issue of ordinary shares
9
Subject to Resolution 7, to
21,393,550
98.60
304,724
1.40
20,000
disapply statutory pre-
emption rights in relation to
the issue of ordinary shares
for specific purposes
Attachments
Original Link
Original Document
Permalink
Disclaimer
Destiny Pharma plc published this content on
12 June 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
13 June 2024 07:45:02 UTC.
Destiny Pharma plc is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of novel medicines that can prevent life-threatening infections. The Company's drug development pipeline includes two late stage assets, NTCD-M3, a microbiome-based biotherapeutic for the prevention of C.difficile infection (CDI) recurrence, which is the principal cause of hospital acquired infection in the United States, and XF-73 nasal gel, a proprietary drug targeting the prevention of postsurgical staphylococcal hospital infections including methicillin-resistant Staphylococcus aureus (MRSA). The Companyâs earlier stage pipeline is focused on other indications including two, separate dermal programmes incorporating its XF platform. It is also collaborating with SporeGen on a novel SPOR-COV innate immune system boosting nasal spray for the prevention of COVID-19 and influenza.
DESTINY PHARMA PLC 
